Literature DB >> 11808862

Pharmacokinetics and toxicity of idarubicin in the rat.

O Kuhlmann1, S Hofmann, M Weiss.   

Abstract

This study was designed to examine the pharmacokinetics and toxicity of idarubicin (IDA) in rats. In two groups of rats IDA was infused either into the V. iugularis interna or into the A. carotis communis, respectively. The venous plasma concentration of IDA and its primary metabolite idarubicinol (IDOL) were measured up to 48 hours by high-performance liquid chromatography (HPLC) with fluorescence detection. The weights of the rats and the levels of haemoglobin, leukocytes, and thrombocytes were recorded. The plasma concentration-time data were analysed, assuming a biexponential disposition curve, both by the traditional (two-stage) method and by population pharmacokinetic modelling. The basic pharmacokinetic parameters clearance (CL = 27.0 ml min(-1)), mean disposition residence time (MDRT = 519.2 min), and volume of distribution at steady state (Vss = 12.51) were estimated for IDA. The mean residence time (MRT) of the generated IDOL was 2982.5 min. No significant differences between pre- and postpulmonal injection were found in the pharmacokinetics and pharmacodynamics of IDA. The mean survival time of 13.3 days is attributed to a severe myelosuppression.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11808862     DOI: 10.1007/BF03226374

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  23 in total

1.  The relevance of residence time theory to pharmacokinetics.

Authors:  M Weiss
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Doxorubicin and doxorubicinol: intra- and inter-individual variations of pharmacokinetic parameters.

Authors:  J M Jacquet; F Bressolle; M Galtier; M Bourrier; D Donadio; J Jourdan; J F Rossi
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Regional chemotherapy via pulmonary artery with blood flow occlusion in a solitary tumor nodule model.

Authors:  H Y Wang; S Hochwald; B Ng; M Burt
Journal:  Anticancer Res       Date:  1996 Nov-Dec       Impact factor: 2.480

4.  Pharmacokinetics and tissue distribution of idarubicin and its active metabolite idarubicinol in the rabbit.

Authors:  M Looby; R Linke; M Weiss
Journal:  Cancer Chemother Pharmacol       Date:  1997       Impact factor: 3.333

5.  Isolated lung perfusion: single-pass system versus recirculating blood perfusion in pigs.

Authors:  M Furrer; D Lardinois; W Thormann; H J Altermatt; D Betticher; T Cerny; A Fikrle; D Mettler; U Althaus; M E Burt; H B Ris
Journal:  Ann Thorac Surg       Date:  1998-05       Impact factor: 4.330

6.  Determination of idarubicin and idarubicinol in rat plasma using reversed-phase high-performance liquid chromatography and fluorescence detection.

Authors:  O Kuhlmann; S Hofmann; M Weiss
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1999-05-28

Review 7.  Clinical pharmacokinetics of idarubicin.

Authors:  J Robert
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

8.  Idarubicin and idarubicinol are less affected by topoisomerase II-related multidrug resistance than is daunorubicin.

Authors:  T Fukushima; H Inoue; H Takemura; S Kishi; T Yamauchi; K Inai; T Nakayama; S Imamura; Y Urasaki; T Nakamura; T Ueda
Journal:  Leuk Res       Date:  1998-07       Impact factor: 3.156

9.  Isolated single-lung perfusion with doxorubicin is pharmacokinetically superior to intravenous injection.

Authors:  B Weksler; B Ng; J T Lenert; M E Burt
Journal:  Ann Thorac Surg       Date:  1993-08       Impact factor: 4.330

10.  Epirubicin as a single agent therapy for the treatment of breast cancer--a pharmacokinetic and clinical study.

Authors:  S Eksborg; L Hardell; N O Bengtsson; M Sjödin; B Elfsson
Journal:  Med Oncol Tumor Pharmacother       Date:  1992
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.